Switzerland· 66578004
Steglujan 5 mg /100 mg, Filmtabletten
A sitagliptin and ertugliflozin product containing ertugliflozinum, sitagliptinum, registered in Switzerland by MSD Merck Sharp & Dohme AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Sitagliptin and ertugliflozin is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BD24 (sitagliptin and ertugliflozin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Sitagliptin and ertugliflozin · ATC A10BD24
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- ertugliflozinum, sitagliptinum
- Manufacturer
- MSD Merck Sharp & Dohme AG
- Country
- Switzerland (CH)
- ATC code
- A10BD24
- ATC class
- Sitagliptin and ertugliflozin
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680665780047Blist 98 StkCHF 238.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sitagliptin and ertugliflozin in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSTEGLUJANMerck Sharp & Dohme B.V., Haarlem
- IcelandSteglujanMerck Sharp & Dohme B.V.*
- PolandSteglujanMerck Sharp & Dohme B.V.
- SwedenSteglujan 15 mg/100 mg Filmdragerad tablettMerck Sharp & Dohme BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Steglujan
- Liechtenstein · Steglujan
- Norway · Steglujan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aa4a6dd7-382f-4e80-83b5-d26ee9087e65 GET /v1/drugs/aa4a6dd7-382f-4e80-83b5-d26ee9087e65?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ertugliflozinum 5 mg + sitagliptinum 100 mg",
"valid_from": "2019-01-01",
"limitations": "[{\"description\":\"Zur Verbesserung des Blutzuckerspiegels bei erwachsenen Patienten mit Diabetes mellitus Typ 2:<br>\\n -\\tanstelle von Ertugliflozin, wenn die Blutzuckerkontrolle durch Diät, Bewegung und eine Behandlung mit Ertugliflozin und Metformin oder mit Ertugliflozin und einem Sulfonylharnstoff unzureichend ist.<br>\\n -\\tanstelle von Sitagliptin, wenn die Blutzuckerkontrolle durch Diät, Bewegung und eine Behandlung mit Sitagliptin und Metformin oder mit Sitagliptin und einem Sulfonylharnstoff unzureichend ist.<br>\\n -\\tAls Ersatz der freien Kombination von Ertugliflozin und Sitagliptin bei erwachsenen Patienten mit Diabetes mellitus Typ 2, welche bereits mit dieser Kombination behandelt werden.<br>\\n -\\tEs wird maximal eine Tagesdosierung von 5 mg Ertugliflozin vergütet.<br>\\n<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2019-01-01\"}]",
"galenic_form": "Filmtabl 5mg/100mg",
"therapeutic_area": null,
"sl_inclusion_date": "2019-01-01",
"self_retention_pct": 10
}See everything about sitagliptin and ertugliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.